NCT04187573已完成不适用
Coil Assisted Flow Diversion: A Prospective, Single Arm, Multi-center Study to Assess the Safety and Performance of Neqstent in Adjunctive Therapy (CAFI Study)
Cerus Endovascular, Inc.9 个研究点 分布在 5 个国家目标入组 38 人开始时间: 2020年1月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 38
- 试验地点
- 9
- 主要终点
- The Proportion of Subjects With Death of Any Non-accidental Cause or Any Major Disabling Stroke After Treatment or Major Disabling Stroke or Death Due to Neurological Cause.
研究概览
简要总结
Cerus Endovascular is sponsoring a prospective, single arm, multi-center study to document the safety and performance of Neqstent in adjunctive therapy.
The purpose of the study is to document safety and performance of the Neqstent in adjunctive therapy in treatment for patients with intracranial aneurysms (IA).
详细描述
Neqstent is designed as an adjunctive therapy for patients with unruptured and failed bifurcation aneurysm embolizations. Neqstent can be positioned at the neck of the aneurysm with or without existing coils and other embolization products. Embolization coils should be added to fill the dome of the aneurysm after placement of Neqstent.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient's indication for treatment of unruptured IAs according to the national/international guidelines.
- •Age 18-80 years at screening
- •Patients who are suitable for non-emergency endovascular embolization of saccular IAs
- •IA located at a bifurcation in the anterior or posterior circulation with dimensions consistent with implant size selection guidelines included in the IFU
- •Patient has the necessary mental capacity to participate and is willing and able to participate in the study for the duration of the study follow-up and is able to comply with study requirements
- •Patient able to able to give their informed consent can be included in this study. This must be demonstrated by means of a personally signed and dated informed consent document indicating that the subject has been informed of and understood all pertinent aspects of the study.
排除标准
- •Ruptured aneurysm
- •Patient anatomy or physiology considered unsuitable for endovascular treatment
- •Any patient anatomy, physiology, existing implants with failed aneurysm embolization that would interfere with the ability for Neqstent to seal at the neck of the aneurysm. (i.e., compacted coils in close proximity to the neck that prevent good apposition of the Neqstent to the wall of the aneurysm, stent and/or stent-like devices whose struts span the aneurysm neck to retain the coil mass that inhibit access and/or successful Neqstent seating at the aneurysm neck, and/or any aneurysm that has a failed device and confirmed thrombus-burden inside the aneurysm sac)
- •Contraindication for arterial access
- •Largest measured IA neck diameter >8 mm or <3 mm
- •Target IA contains other devices/implants (e.g., coils) that will prevent complete expansion of Neqstent
- •Known allergy to platinum, nickel or titanium
- •Known allergy to contrast agents
- •Contraindication to anticoagulants or platelet inhibitor medication
- •Stenosis of the target IA's parent vessel >50%
- •Anticoagulation medications such as warfarin that cannot be discontinued.
- •Pregnant, breastfeeding or women of childbearing potential not on adequate birth control (only women with a highly effective method of contraception [oral contraception or intra-uterine device] or sterile women can be enrolled to the study)
- •Acute / chronic renal failure (including dialysis); Creatinine > 2.00 mg/dl or > 182 μmol/L
- •Myocardial Infarction, Stroke or TIA within the last 6 months
- •Any other medical issue within the brain that precludes the device implantation such as brain surgery, radiation in the target area of intervention, acute traumatic craniocerebral injury, etc.
- •Other medical conditions that cause an inability to comply with study requirements and/or that could increase the risk of neurovascular procedures or death within 2 years (e.g., liver failure, cancer, heart failure, chronic obstructive pulmonary disease, immunosuppression, neural disease, and hematologic disorders etc.)
- •Participating in another study with investigational devices or drugs that would confound the effects of the study outcomes
- •The presence of condition that may create unacceptable risk during the aneurysm embolization procedure
结局指标
主要结局
The Proportion of Subjects With Death of Any Non-accidental Cause or Any Major Disabling Stroke After Treatment or Major Disabling Stroke or Death Due to Neurological Cause.
时间窗: From day 31 to 6 months after treatment
The Proportion of Subjects With Complete Occlusion
时间窗: 6 months
Success will be defined as complete occlusion demonstrated by a Grade 1 using the Raymond Roy Scale.
次要结局
未报告次要终点
研究者
研究点 (9)
Loading locations...
相似试验
Unknown
不适用
Endovascular Denervation for the Treatment of Type 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)NCT05631561Shanghai Golden Leaf MedTec Co. Ltd30
Unknown
不适用
PDCN for Treatment of Cervical VertigoCervical VertigoNCT03485768Third Affiliated Hospital, Sun Yat-Sen University70
尚未招募
不适用
Clinical Study of Endovascular Interventional Surgical Instrument Control System and Related Consumables in Lower Extremity Arteriosclerosis Occlusive LumenPeripheral Arterial DiseaseNCT05625711Shanghai Operation Robot Co., Ltd.260
已完成
不适用
Flow Diversion in Intracranial Aneurysm TreatmentIntracranial AneurysmNCT01349582Centre hospitalier de l'Université de Montréal (CHUM)323
招募中
不适用
Prospective, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Endovascular Treatment in Patients With Cerebral Aneurysms Using P64 and P48 Flow-Diverter StentsCerebral AneurysmThromboembolic DiseaseNCT06201598Hospital Universitario Central de Asturias100